Fresenius Medical Care
Fresenius Medical Care's revenue rose 1.5% to €19.6 billion in fiscal 2025. Its operating margin was 9.3%, up from 7.2% a year earlier. It paid out €1.0 billion in dividends and buybacks. The diluted share count fell 0.8%.
Operating margin is operating income as a share of revenue. Free cash flow is cash from operations minus capital spending. Return on capital is after-tax operating income as a share of the money invested in the business: debt plus equity, minus cash.
What Fresenius Medical Care does
Fresenius Medical Care provides products and services for people with kidney disease. It describes itself as the world's largest provider by publicly reported revenue. It combines medical device manufacturing with patient care, mainly dialysis, a procedure that cleans the blood when the kidneys fail.
It runs three segments: Care Delivery (its dialysis clinics and related services), Value-Based Care (programs in which it manages the cost and quality of care for groups of patients) and Care Enablement (the products it makes and sells, such as dialysis machines, supplies and pharmaceuticals). It sells products to customers in more than 140 countries and operates 35 production sites in 19 countries.
At the end of 2025 it operated 3,601 dialysis centers in more than 30 countries, serving 291,902 patients, down from the year before after it sold some operations. It had 109,698 employees.
Its biggest risks, as it describes them
- Changes in government reimbursement, payor mix or healthcare rules that could cut its revenue and profit.
- Legislative reform of its highly regulated industry that could change how it operates.
- Rules on its value-based care programs and investments, with legal exposure if found to violate the law.
- Losing patient referrals from doctors, and competitors with better technology or generic drugs.
- Product liability and patent claims, and cyber-attacks or data breaches.
Income statement
From fiscal 2016 to 2025, earnings per share fell 1.2% a year and net income 1.7% a year, while buybacks cut the share count by 5%.
Returns on capital
Balance sheet
Five years at a glance
| Fiscal year end | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|
| Cash and short-term investments | 1,482 | 1,274 | 1,404 | 1,180 | 1,599 |
| Debt incl. finance leases | 8,571 | 8,514 | 7,904 | 6,838 | 7,288 |
| Net debt (negative means net cash) | 7,089 | 7,240 | 6,501 | 5,658 | 5,689 |
| Net debt to EBITDA | 2.1x | 2.2x | 2.2x | 1.9x | 1.7x |
| Debt to equity | 0.7x | 0.6x | 0.6x | 0.5x | 0.6x |
| Interest coverage | 5.4x | 4.2x | 3.2x | 3.5x | 4.9x |
| Current ratio | 1.1x | 1.3x | 1.4x | 1.4x | 1.3x |
| Quick ratio | 0.8x | 0.9x | 1.1x | 1.0x | 0.9x |
Cash flow
Indicators
Four widely used measures, worked out from the company's filings. The cutoffs are the ones their authors or users go by, not a verdict of ours.
| Indicator | FY23 | FY24 | FY25 |
|---|---|---|---|
| Piotroski F-score | 5 of 9 | 7 of 9 | 7 of 9 |
| Rule of 40 | — | — | — |
| Altman Z'' | 2.64 | 2.75 | 2.93 |
| Accruals ratio | −6.1% | −5.5% | −5.3% |
The nine F-score tests
| Test | FY23 | FY24 | FY25 |
|---|---|---|---|
| Net income is positive | Pass | Pass | Pass |
| Cash from operations is positive | Pass | Pass | Pass |
| Return on assets rose | Fail | Pass | Pass |
| Cash from operations exceeds net income | Pass | Pass | Pass |
| Debt fell relative to assets | Pass | Pass | Fail |
| Current ratio rose | Pass | Fail | Fail |
| Share count didn't rise | Fail | Pass | Pass |
| Gross margin rose | Fail | Fail | Pass |
| Revenue rose relative to assets | Fail | Pass | Pass |
| F-score | 5 of 9 | 7 of 9 | 7 of 9 |
Compare
Put Fresenius Medical Care side by side with any other company we cover: revenue, growth, margins, cash flow and returns, with ten years of charts.
Similar companies
| Company | Year | Revenue growth | Operating margin | Free cash flow margin | Return on capital | Net debt to EBITDA | F-score | Compare |
|---|---|---|---|---|---|---|---|---|
| Fresenius Medical Care | FY25 | 1.5% | 9.3% | — | 7.0% | 1.7x | 7 | |
| Labcorp | FY25 | 7.2% | 9.9% | 8.6% | 8.2% | 2.5x | 7 | Compare |
| DaVita | FY25 | 6.5% | 15.0% | 9.6% | 17.6% | 3.5x | 6 | Compare |
| BrightSpring Health Services | FY25 | 28.2% | 2.3% | 3.1% | 5.2% | 5.3x | 7 | Compare |
| Quest Diagnostics | FY25 | 11.8% | 14.1% | 12.3% | 9.5% | 2.5x | 6 | Compare |
10 years of figures
| Fiscal year | FY16 | FY17 | FY18 | FY19 | FY20 | FY21 | FY22 | FY23 | FY24 | FY25 |
|---|---|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||||
| Revenue | 16,570 | 17,784 | 16,547 | 17,477 | 17,859 | 17,619 | 19,398 | 19,454 | 19,336 | 19,628 |
| Revenue growth | 7.2% | 7.3% | −7.0% | 5.6% | 2.2% | −1.4% | 10.1% | 0.3% | −0.6% | 1.5% |
| Gross profit | 5,616 | 6,018 | 5,155 | 5,396 | 5,537 | 5,077 | 5,310 | 4,925 | 4,757 | 5,029 |
| Research and development | 146 | 111 | 114 | 168 | 194 | 221 | 229 | 232 | 184 | 158 |
| Operating income | 2,409 | 2,362 | 3,038 | 2,270 | 2,304 | 1,852 | 1,512 | 1,369 | 1,392 | 1,827 |
| Net income | 1,144 | 1,280 | 1,982 | 1,200 | 1,164 | 969 | 673 | 499 | 538 | 978 |
| Diluted EPS (EUR) | 3.73 | 4.16 | 6.45 | 3.96 | 3.96 | 3.31 | 2.30 | 1.70 | 1.83 | 3.36 |
| Diluted shares (millions) | 306 | 307 | 306 | 303 | 294 | 293 | 293 | 293 | 293 | 291 |
| Cash flow | ||||||||||
| Cash from operations | 1,932 | 2,192 | 2,062 | 2,567 | 4,233 | 2,490 | 2,167 | 2,629 | 2,386 | 2,681 |
| Capital expenditure | 930 | 944 | 1,057 | 1,125 | — | — | — | — | — | — |
| Free cash flow | 1,001 | 1,247 | 1,005 | 1,442 | — | — | — | — | — | — |
| Dividends paid | 244 | 294 | 325 | 355 | 351 | 392 | 396 | 329 | 349 | 422 |
| Share buybacks | 0 | 58 | 37 | 600 | 366 | 0 | 0 | 0 | 0 | 585 |
| Acquisitions | 0 | 521 | 250 | 2,160 | 215 | 325 | 10 | 3 | 0 | 15 |
| Stock-based compensation | 27 | 47 | 11 | 2 | — | — | — | — | — | — |
| Balance sheet at fiscal year end | ||||||||||
| Cash and short-term investments | 709 | 978 | 2,245 | 1,008 | 1,082 | 1,482 | 1,274 | 1,404 | 1,180 | 1,599 |
| Debt incl. finance leases | 8,129 | 7,439 | 7,357 | 9,077 | 7,888 | 8,571 | 8,514 | 7,904 | 6,838 | 7,288 |
| Total assets | 25,504 | 24,025 | 26,242 | 32,935 | 31,689 | 34,367 | 35,754 | 33,930 | 33,567 | 31,002 |
| Total liabilities | 14,452 | 13,197 | 13,340 | 19,708 | 19,358 | 20,388 | 20,305 | 19,103 | 17,798 | 16,720 |
| Shareholders' equity | 9,978 | 9,820 | 11,758 | 11,958 | 11,215 | 12,699 | 13,990 | 13,620 | 14,577 | 13,310 |
| Margins and ratios | ||||||||||
| Gross margin | 33.9% | 33.8% | 31.1% | 30.9% | 31.0% | 28.8% | 27.4% | 25.3% | 24.6% | 25.6% |
| Operating margin | 14.5% | 13.3% | 18.4% | 13.0% | 12.9% | 10.5% | 7.8% | 7.0% | 7.2% | 9.3% |
| Net margin | 6.9% | 7.2% | 12.0% | 6.9% | 6.5% | 5.5% | 3.5% | 2.6% | 2.8% | 5.0% |
| Free cash flow margin | 6.0% | 7.0% | 6.1% | 8.2% | — | — | — | — | — | — |
| Rule of 40 (growth + FCF margin) | 13.3% | 14.3% | −0.9% | 13.9% | — | — | — | — | — | — |
| Return on capital | — | 10.3% | 14.0% | 9.0% | 8.4% | 7.2% | 5.1% | 4.4% | 4.6% | 7.0% |
| Return on equity | — | 12.9% | 18.4% | 10.1% | 10.1% | 8.1% | 5.0% | 3.6% | 3.8% | 7.0% |
| Return on assets | — | 5.2% | 7.9% | 4.0% | 3.6% | 2.9% | 1.9% | 1.4% | 1.6% | 3.0% |
| Net debt to EBITDA | 4.3x | 2.1x | 1.4x | 2.1x | 1.8x | 2.1x | 2.2x | 2.2x | 1.9x | 1.7x |